OBJECTIVE: To assess haematological and biochemical parameters in Human Immunodeficiency Virus (HIV) patients under going antiretroviral therapy. METHODS: We enrolled HIV patients from, 18-65 years, who were under first line antiretroviral therapy and followed them for six months from February 2010 for changes in haematological and biochemical parameters. Profiles for ALAT, creatinine, amylase, cholesterol, CD4+ and total lymphocytes, haemoglobin, and monocytes were studied every three months. RESULTS: There was an increase of both, CD4+ lymphocyte counts from 233.57 cells/mm(3) to 336.45 cells/mm(3) and total lymphocytes from 45 to 46.6 10(3) cells /µl, after six months. The haemoglobin level dropped from 8.8 g/L to 7.52 g/L. We observed an increase in ALAT from 40.27 to 47.42 U/L, amylase from 178.9 to 193.97 U/L, and cholesterol from 5.88 to 8.40 mmol/L. Creatinine levels decreased from 117.4 to 115.0 µmol/L. CONCLUSION: The use of ARVs boosts CD4+ and total lymphocyte counts. Prolonged use of antiretroviral drugs (ARVs) is associated with variable degrees of liver and pancreatic damage, hypercholesteremia, and anaemia in some patients. Since many of these side effects are multi-factorial, management of HIV patients should take into consideration such side effects in making treatment decisions based on periodic evaluation of these parameters.
OBJECTIVE: To assess haematological and biochemical parameters in Human Immunodeficiency Virus (HIV) patients under going antiretroviral therapy. METHODS: We enrolled HIVpatients from, 18-65 years, who were under first line antiretroviral therapy and followed them for six months from February 2010 for changes in haematological and biochemical parameters. Profiles for ALAT, creatinine, amylase, cholesterol, CD4+ and total lymphocytes, haemoglobin, and monocytes were studied every three months. RESULTS: There was an increase of both, CD4+ lymphocyte counts from 233.57 cells/mm(3) to 336.45 cells/mm(3) and total lymphocytes from 45 to 46.6 10(3) cells /µl, after six months. The haemoglobin level dropped from 8.8 g/L to 7.52 g/L. We observed an increase in ALAT from 40.27 to 47.42 U/L, amylase from 178.9 to 193.97 U/L, and cholesterol from 5.88 to 8.40 mmol/L. Creatinine levels decreased from 117.4 to 115.0 µmol/L. CONCLUSION: The use of ARVs boosts CD4+ and total lymphocyte counts. Prolonged use of antiretroviral drugs (ARVs) is associated with variable degrees of liver and pancreatic damage, hypercholesteremia, and anaemia in some patients. Since many of these side effects are multi-factorial, management of HIVpatients should take into consideration such side effects in making treatment decisions based on periodic evaluation of these parameters.
Authors: E S Rosenberg; M Altfeld; S H Poon; M N Phillips; B M Wilkes; R L Eldridge; G K Robbins; R T D'Aquila; P J Goulder; B D Walker Journal: Nature Date: 2000-09-28 Impact factor: 49.962
Authors: Timothy W Schacker; Ronald J Bosch; Kara Bennett; Richard Pollard; Gregory K Robbins; Ann C Collier; Roy M Gulick; John Spritzler; Donna Mildvan Journal: J Acquir Immune Defic Syndr Date: 2010-05-01 Impact factor: 3.731
Authors: S M Hammer; K E Squires; M D Hughes; J M Grimes; L M Demeter; J S Currier; J J Eron; J E Feinberg; H H Balfour; L R Deyton; J A Chodakewitz; M A Fischl Journal: N Engl J Med Date: 1997-09-11 Impact factor: 91.245
Authors: Emmanuel O Idigbe; Taiwo A Adewole; Geoffrey Eisen; Phyllis Kanki; Nkiru N Odunukwe; Dan I Onwujekwe; Rosemary A Audu; Idowu D Araoyinbo; Joseph I Onyewuche; Oluwamuyiwa B Salu; John A Adedoyin; Adesola Z Musa Journal: J Acquir Immune Defic Syndr Date: 2005-09-01 Impact factor: 3.731
Authors: C Pryce; R B Pierre; J Steel-Duncan; T Evans-Gilbert; P Palmer; J Moore; B Rodriguez; C D C Christie Journal: West Indian Med J Date: 2008-06 Impact factor: 0.171
Authors: Devan Jaganath; A Sarah Walker; Francis Ssali; Victor Musiime; Francis Kiweewa; Cissy Kityo; Robert Salata; Peter Mugyenyi Journal: AIDS Res Hum Retroviruses Date: 2014-02-07 Impact factor: 2.205
Authors: Augustine O Ebonyi; Stephen Oguche; Martha O Ochoga; Oche O Agbaji; Joseph A Anejo-Okopi; Isaac O Abah; Prosper I Okonkwo; John A Idoko Journal: J Virus Erad Date: 2017-10-01